Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 22 July 2026
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC